{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T03:21:58Z","timestamp":1786332118581,"version":"build-2736575974"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Neurology and Neurosurgery"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.clineuro.2019.04.013","type":"journal-article","created":{"date-parts":[[2019,4,15]],"date-time":"2019-04-15T12:10:26Z","timestamp":1555330226000},"page":"76-81","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Dabigatran reversal by idarucizumab in the setting of intracranial hemorrhage: A systematic review of the literature"],"prefix":"10.1016","volume":"181","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9470-5890","authenticated-orcid":false,"given":"Victor M.","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Phan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashanth J.","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunjay V.","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekkehard M.","family":"Kasper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.clineuro.2019.04.013_bib0005","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1001\/jama.285.18.2370","article-title":"Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study","volume":"285","author":"Go","year":"2001","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.clineuro.2019.04.013_bib0010","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1016\/j.ijcard.2012.12.093","article-title":"Atrial fibrillation: profile and burden of an evolving epidemic in the 21st century","volume":"167","author":"Ball","year":"2013","journal-title":"Int. J. Cardiol."},{"issue":"8","key":"10.1016\/j.clineuro.2019.04.013_bib0015","first-page":"1471","article-title":"Oral anticoagulants and intracranial hemorrhage","volume":"26","author":"Hart","year":"1995","journal-title":"Facts and hypotheses. Stroke."},{"issue":"11","key":"10.1016\/j.clineuro.2019.04.013_bib0020","doi-asserted-by":"crossref","first-page":"791","DOI":"10.3949\/ccjm.77a.10018","article-title":"Should anticoagulation be resumed after intracerebral hemorrhage?","volume":"77","author":"Goldstein","year":"2010","journal-title":"Cleve. Clin. J. Med."},{"issue":"2","key":"10.1016\/j.clineuro.2019.04.013_bib0025","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1212\/01.wnl.0000250340.05202.8b","article-title":"The increasing incidence of anticoagulant-associated intracerebral hemorrhage","volume":"68","author":"Flaherty","year":"2007","journal-title":"Neurology."},{"issue":"8","key":"10.1016\/j.clineuro.2019.04.013_bib0030","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1055\/s-0037-1602377","article-title":"Bleeding Complications and Management on anticoagulant therapy","volume":"43","author":"Schulman","year":"2017","journal-title":"Semin. Thromb. Hemost."},{"issue":"5","key":"10.1016\/j.clineuro.2019.04.013_bib0035","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1046\/j.1365-2796.2003.01209.x","article-title":"Risk of haemorrhagic stroke in patients with oral anticoagulation compared with the general population","volume":"254","author":"Sj\u00e4lander","year":"2003","journal-title":"J. Intern. Med. (GBR)."},{"issue":"12","key":"10.1016\/j.clineuro.2019.04.013_bib0040","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1161\/01.CIR.0000063575.17904.4E","article-title":"American heart Association\/American college of cardiology foundation guide to warfarin therapy","volume":"107","author":"Hirsh","year":"2003","journal-title":"Circulation."},{"issue":"4","key":"10.1016\/j.clineuro.2019.04.013_bib0045","doi-asserted-by":"crossref","first-page":"198","DOI":"10.5694\/mja12.10614","article-title":"An update of consensus guidelines for warfarin reversal","volume":"198","author":"Tran","year":"2013","journal-title":"Med. J. Aust."},{"issue":"2","key":"10.1016\/j.clineuro.2019.04.013_bib0050","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s13181-012-0276-5","article-title":"Positive outcome after intentional overdose of dabigatran","volume":"9","author":"Woo","year":"2013","journal-title":"J. Med. Toxicol."},{"issue":"5","key":"10.1016\/j.clineuro.2019.04.013_bib0055","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1097\/ALN.0000000000001856","article-title":"Reversing dabigatran anticoagulation with prothrombin complex concentrate versus idarucizumab as part of multimodal hemostatic intervention in an animal model of Polytrauma","volume":"127","author":"Honickel","year":"2017","journal-title":"Anesthesiology."},{"issue":"1","key":"10.1016\/j.clineuro.2019.04.013_bib0060","doi-asserted-by":"crossref","first-page":"e172","DOI":"10.1111\/j.1365-2516.2010.02352.x","article-title":"First 20 years with recombinant FVIIa (NovoSeven)","volume":"17","author":"Hedner","year":"2011","journal-title":"Haemophilia"},{"issue":"2","key":"10.1016\/j.clineuro.2019.04.013_bib0065","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1136\/emermed-2012-201976","article-title":"The acute management of haemorrhage, surgery and overdose in patients receiving dabigatran","volume":"31","author":"Alikhan","year":"2014","journal-title":"Emerg. Med. J."},{"issue":"5","key":"10.1016\/j.clineuro.2019.04.013_bib0070","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1056\/NEJMoa1707278","article-title":"Idarucizumab for dabigatran reversal - full cohort analysis","volume":"377","author":"Pollack","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.clineuro.2019.04.013_bib0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med."},{"key":"10.1016\/j.clineuro.2019.04.013_bib0080","first-page":"358","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","author":"Shea","year":"2017","journal-title":"BMJ (Clinical research ed.)"},{"issue":"4","key":"10.1016\/j.clineuro.2019.04.013_bib0085","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1177\/1747493017701944","article-title":"Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany - A national case collection","volume":"12","author":"Kermer","year":"2017","journal-title":"Int. J. Stroke"},{"issue":"3","key":"10.1016\/j.clineuro.2019.04.013_bib0090","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/s11239-017-1476-2","article-title":"Real-life experience with the specific reversal agent idarucizumab for the management of emergency situations in dabigatran-treated patients: a series of 11 cases","volume":"43","author":"Vosko","year":"2017","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/j.clineuro.2019.04.013_bib0095","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.wneu.2017.10.043","article-title":"Safe burr hole surgery for chronic subdural hematoma using dabigatran with idarucizumab","volume":"109","author":"Arai","year":"2018","journal-title":"World Neurosurg."},{"issue":"4","key":"10.1016\/j.clineuro.2019.04.013_bib0100","first-page":"349","article-title":"Reversal of Dabigatran with idarucizumab in acute subarachnoid hemorrhage","volume":"1","author":"Balakumar","year":"2017","journal-title":"Clin. Pract. Cases Emerg. Med."},{"key":"10.1016\/j.clineuro.2019.04.013_bib0105","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.tcr.2017.12.003","article-title":"Use of Idarucizumab for dabigatran reversal: emergency department experience in two cases with subdural haematoma","volume":"13","author":"Edwards","year":"2018","journal-title":"Trauma Case Rep."},{"issue":"3","key":"10.1016\/j.clineuro.2019.04.013_bib0110","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/ccr3.839","article-title":"Real-world use of idarucizumab for dabigatran reversal in three cases of serious bleeding","volume":"5","author":"Gendron","year":"2017","journal-title":"Clin. Case Rep."},{"issue":"11","key":"10.1016\/j.clineuro.2019.04.013_bib0115","first-page":"699","article-title":"The use of idarucizumab for dabigatran reversal in clinical practice: a case series","volume":"42","author":"Goriacko","year":"2017","journal-title":"P & T : a peer-review. J. formul. manag"},{"issue":"1","key":"10.1016\/j.clineuro.2019.04.013_bib0120","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s40520-017-0752-5","article-title":"Increased dabigatran plasma concentration during Ibrutinib treatment: a case of cerebral hemorrhage and successful dabigatran reversal by idarucizumab","volume":"30","author":"Quintavalla","year":"2018","journal-title":"Aging Clin. Exp. Res."},{"issue":"1","key":"10.1016\/j.clineuro.2019.04.013_bib0125","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11239-018-1658-6","article-title":"Reversal of dabigatran using idarucizumab: single center experience in four acute stroke patients","volume":"46","author":"Hieber","year":"2018","journal-title":"J. Thromb. Thrombolysis"},{"issue":"3","key":"10.1016\/j.clineuro.2019.04.013_bib0130","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1159\/000452096","article-title":"Idarucizumab as antidote to Intracerebral Hemorrhage under treatment with Dabigatran","volume":"8","author":"Held","year":"2016","journal-title":"Case Rep. Neurol."},{"key":"10.1016\/j.clineuro.2019.04.013_bib0135","series-title":"Idarucizumab for Dabigatran Reversal in Life-threatening Bleeding (subdural Haematoma). A Case Report","author":"Manotti","year":"2016"},{"issue":"8","key":"10.1016\/j.clineuro.2019.04.013_bib0140","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1161\/STROKEAHA.114.006016","article-title":"Intracranial hemorrhage mortality in atrial fibrillation patients treated with dabigatran or warfarin","volume":"45","author":"Alonso","year":"2014","journal-title":"Stroke."},{"issue":"2","key":"10.1016\/j.clineuro.2019.04.013_bib0145","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1001\/jamaneurol.2015.3682","article-title":"Early clinical and radiological course, management, and outcome of intracerebral hemorrhage related to new oral anticoagulants","volume":"73","author":"Purrucker","year":"2016","journal-title":"JAMA Neurol."},{"issue":"1","key":"10.1016\/j.clineuro.2019.04.013_bib0150","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1160\/TH14-04-0361","article-title":"Evaluating the use of commercial drug-specific calibrators for determining PT and APTT reagent sensitivity to dabigatran and rivaroxaban","volume":"113","author":"Gosselin","year":"2015","journal-title":"Thromb. Haemost."},{"issue":"1","key":"10.1016\/j.clineuro.2019.04.013_bib0155","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1160\/TH14-02-0161","article-title":"Influence of dabigatran and rivaroxaban on routine coagulation assays. A nationwide Belgian survey","volume":"113","author":"Van Blerk","year":"2015","journal-title":"Thromb. Haemost."},{"issue":"3","key":"10.1016\/j.clineuro.2019.04.013_bib0160","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.thromres.2015.07.018","article-title":"Is Thrombin Time useful for the assessment of dabigatran concentrations? An in vitro and ex vivo study","volume":"136","author":"Lessire","year":"2015","journal-title":"Thromb. Res."},{"issue":"6","key":"10.1016\/j.clineuro.2019.04.013_bib0165","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1160\/TH09-11-0758","article-title":"Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity","volume":"103","author":"van Ryn","year":"2010","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.clineuro.2019.04.013_bib0170","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jocn.2015.11.024","article-title":"Normalization of coagulopathy is associated with improved outcome after isolated traumatic brain injury","volume":"29","author":"Epstein","year":"2016","journal-title":"J. Clin. Neurosci."},{"issue":"8","key":"10.1016\/j.clineuro.2019.04.013_bib0175","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1001\/jama.2015.0846","article-title":"Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage","volume":"313","author":"Kuramatsu","year":"2015","journal-title":"JAMA."},{"issue":"5","key":"10.1016\/j.clineuro.2019.04.013_bib0180","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1177\/1076029618755947","article-title":"The renal elimination pathways of the dabigatran reversal agent idarucizumab and its impact on dabigatran elimination","volume":"24","author":"Glund","year":"2018","journal-title":"Clin. Appl. Thromb. Hemost."},{"issue":"17","key":"10.1016\/j.clineuro.2019.04.013_bib0185","first-page":"1690","article-title":"Dabigatran reversal with Idarucizumab. The New England journal of","volume":"377","author":"Yip","year":"2017","journal-title":"medicine"},{"issue":"6","key":"10.1016\/j.clineuro.2019.04.013_bib0190","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1502000","article-title":"Idarucizumab for dabigatran reversal","volume":"373","author":"Pollack","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.clineuro.2019.04.013_bib0195","doi-asserted-by":"crossref","first-page":"3594","DOI":"10.1161\/STROKEAHA.111.624650","article-title":"Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran","volume":"42","author":"Zhou","year":"2011","journal-title":"Stroke."},{"issue":"3","key":"10.1016\/j.clineuro.2019.04.013_bib0200","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1080\/15563650.2017.1349911","article-title":"Incomplete dabigatran reversal with idarucizumab","volume":"56","author":"Steele","year":"2018","journal-title":"Clin. Toxicol. Phila. (Phila)"},{"issue":"3","key":"10.1016\/j.clineuro.2019.04.013_bib0205","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/HPC.0000000000000076","article-title":"Idarucizumab (Praxbind) formulary review","volume":"15","author":"Buchheit","year":"2016","journal-title":"Crit. Pathw. Cardiol."},{"issue":"17","key":"10.1016\/j.clineuro.2019.04.013_bib0210","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1056\/NEJMc1711337","article-title":"Dabigatran reversal with Idarucizumab","volume":"377","author":"Radecki","year":"2017","journal-title":"N. Engl. J. Med."}],"container-title":["Clinical Neurology and Neurosurgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303846719301167?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303846719301167?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T14:29:36Z","timestamp":1759588176000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0303846719301167"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":42,"alternative-id":["S0303846719301167"],"URL":"https:\/\/doi.org\/10.1016\/j.clineuro.2019.04.013","relation":{},"ISSN":["0303-8467"],"issn-type":[{"value":"0303-8467","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dabigatran reversal by idarucizumab in the setting of intracranial hemorrhage: A systematic review of the literature","name":"articletitle","label":"Article Title"},{"value":"Clinical Neurology and Neurosurgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clineuro.2019.04.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}